Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial

Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial

Introduction About 25% of patients with COVID-19 develop acute respiratory distress syndrome (ARDS) associated with a high release of pro-inflammatory cytokines such as interleukin-6 (IL-6). The aim of the SARICOR study is to demonstrate that early administration of sarilumab (an IL-6 receptor inhib...

Full description

Bibliographic Details
Main Authors: Antonio Luque-Pineda, Julian Torre-Cisneros, M Ángeles Esteban-Moreno, Rafael León López, Sheila Cárcel Fernández, Laura Limia Pérez, Alberto Romero Palacios, María Concepción Fernández-Roldán, Eduardo Aguilar Alonso, Inés Pérez Camacho, Nicolás Merchante, Julián Olalla, Marta Santos
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/11/e039951.full

Internet

https://bmjopen.bmj.com/content/10/11/e039951.full

Similar Items